Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL

Enrollment

278

Participants

Timeline

Start Date

June 13, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

June 30, 2008

Conditions

Major Depressive Disorder

Interventions

DRUG

ONO-2333Ms Experimental 2

5-10 mg QD(once a day) for 8 weeks

DRUG

Placebo

0 mg QD(once a day) for 8 weeks

DRUG

ONO-2333Ms Experimental 1

1-2 mg QD(once a day) for 8 weeks

Trial Locations (1)

Ono Pharma Investigtional Site, Atlanta